Core Laboratories Inc. /DE/

Annual Trend FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Net income $20.2m $19.7m $37.0m $32.2m $30.4m
Depreciation and amortization $18.5m $17.2m $15.8m $15.0m $14.6m
Deferred income taxes $6.0m $433k ($10.8m) $674k $1.4m
Stock-based compensation $19.1m $7.8m $14.0m $3.8m $7.1m
Assets write-down $0 $1.1m $1.1m $34k
Inventory write-off and obsolescence ($142k) $1.7m $2.9m $2.3m
Net provision for credit losses ($256k) ($6k) $179k $1.2m $3.4m
Changes in value of life insurance policies ($2.7m) $5.1m ($5.0m) ($2.8m) ($1.9m)
Realization of pension obligation ($234k) $451k ($892k) ($33k) $337k
Other non-cash items ($2.5m) ($547k) $3.3m ($1.0m) $682k
Accounts receivable ($13.5m) ($10.1m) ($2.6m) ($3.6m) ($5.0m)
Inventories ($4.5m) ($14.9m) ($13.0m) $9.4m $2.6m
Prepaid expenses and other current assets $1.8m ($76k) $2.0m ($5.7m) ($1.2m)
Other assets ($523k) ($1.4m) $1.5m ($289k) $28k
Accounts payable $6.6m $15.4m ($12.9m) $519k $477k
Accrued expenses ($8.8m) ($1.3m) ($375k) $2.5m ($2.7m)
Unearned revenues $2.3m ($1.8m) ($1.2m) $4.6m ($3.8m)
Other liabilities ($3.9m) ($10.9m) ($2.2m) $460k ($5.1m)
Proceeds from insurance recovery - Aberdeen facility $726k $583k $0 $2.1m $10.0m
Proceeds from sale of assets $678k $1.9m $485k $1.7m $3.0m
Patents and other intangibles ($318k) ($29k) $67k $20k ($150k)
Acquisitions, net of cash acquired $0 $0 ($1.2m)
Net proceeds on life insurance policies $1.4m $3.7m $3.4m $2.8m $778k
Equity related transaction costs ($861k) ($411k) ($4.1m) ($756k) $0
Cash payments for interest $10.5m $9.3m $11.2m $10.9m $8.2m
Cash payments for income taxes $9.1m $14.1m $16.0m $17.6m $18.7m
Restricted shares withheld from employees for settlement of tax liabilities $0 $0 $3.1m
Business acquisition contingent cash consideration $0 $0 $4.1m
Equity related transaction costs incurred but not paid for as of the end of the year $0 $0 $756k $0 $0
Net cash provided by operating activities $36.6m $25.0m $24.8m $56.4m $37.0m
Insurance recovery on property, plant and equipment $0 $0 ($4.4m) ($6.8m)
Capital expenditures - operations ($13.5m) ($10.2m) ($10.6m) ($13.0m) ($11.2m)
Capital expenditures - rebuilding of Aberdeen facility $0 ($1.1m) ($3.4m)
Capital expenditures incurred but not paid for as of the end of the year $1.4m $1.2m $963k $1.7m $1.5m
Net cash used in investing activities ($10.2m) ($3.9m) ($6.7m) ($6.4m) ($2.2m)
Proceeds from long-term debt $155.0m $116.0m $202.0m $44.0m $48.0m
Debt issuance costs $0 ($2.2m) ($1.3m) ($19k) ($1.7m)
Repayment of long-term debt ($226.0m) ($131.0m) ($211.0m) ($82.0m) ($63.0m)
Repurchase of common stock ($8.3m) ($3.9m) ($2.2m) ($5.3m) ($12.4m)
Dividends paid ($1.8m) ($1.9m) ($1.9m) ($1.9m) ($1.9m)
Other financing activities ($508k) ($2k) ($54k) $0 ($254k)
Net cash used in financing activities ($22.5m) ($23.4m) ($18.4m) ($46.0m) ($31.3m)
NET CHANGE IN CASH AND CASH EQUIVALENTS $3.9m ($2.3m) ($308k) $4.0m $3.5m
CASH AND CASH EQUIVALENTS, beginning of year $17.7m $15.4m $15.1m $19.2m $22.7m